The LifeSite Hemodialysis Access System in patients with limited access  by Rayan, Sunil S et al.
From the Society for Clinical Vascular Surgery
The LifeSite Hemodialysis Access System in
patients with limited access
Sunil S. Rayan, MD, Thomas T. Terramani, MD, Victor J. Weiss, MD, and Elliot L. Chaikof, MD, PhD,
Atlanta, Ga
Objective: The LifeSite Hemodialysis Access System was recently introduced as a completely subcutaneous device with
reported advantages of improved patient comfort and reduced catheter-related infection. The performance of the LifeSite
catheter at a single, tertiary-care university medical center was reviewed.
Methods: We retrospectively reviewed all patients who underwent placement of the LifeSite catheter between February
2001 and March 2002. Kaplan–Meier analysis was used to determine the probability of patient survival, freedom from
catheter-related infection, and freedom from device failure necessitating catheter removal.
Results: Thirty-six patients who had previously received dialysis for an average of 6.1 years underwent placement of 37
LifeSite catheters. Most patients (95%) were referred for LifeSite placement because they had exhausted all available
arteriovenous fistula and graft sites. Mean follow-up was 6.8 months, with a patient survival rate of 81% at 8 months.
Primary and secondary patency rates were 62% and 87% at 8 months, respectively. Two patients died from infectious
device-related complications. Twelve of 17 patients (71%) with device-related infection did not manifest any signs or
symptoms at the valve site. There were 2.4 catheter-related infections and 2.6 device failures requiring removal per 1000
patient-catheter days. Freedom from infection and device removal at 8 months was 46% and 49%, respectively.
Conclusions: The LifeSite demonstrated acceptable patency, infection, and device failure rates; however, in patients with
limited access, unrecognized infection and death may occur. The LifeSite should not be used as a substitute for a more
permanent form of hemodialysis access. (J Vasc Surg 2003;38:714-8.)
According to the United States Renal Data System
(http://www.USRDS.org), the prevalence of end-stage
renal disease (ESRD) in the United States has grown from
195,000 in 1991 to over 350,000 in 2000. Consequently,
rising costs associated with vascular access have approached
$200 million. Complications associated with vascular ac-
cess account for much of the problem. The USRDS reports
that hemodialysis access failure is the most frequent cause of
hospitalization among ESRD patients, and in some centers,
it accounts for the largest number of hospital days.1 Arte-
riovenous fistulae and grafts are the means by which most
patients are dialyzed in the United States. Tunneled dialysis
catheters (TDC), however, provide a temporary solution
until more permanent access is achieved. Until now, all
TDC have been at least partially external and have been
prone to such problems as patient discomfort, infection,
diminished flow rates, and venous thrombosis.2 The
LifeSite Hemodialysis Access System (Vasca Inc., Tewks-
bury, Mass) was specifically designed to correct some of the
problems inherent in existing TDC.
The LifeSite, as described elsewhere, uses two separate
entirely subcutaneous cannulas to provide hemodialysis
access.3 Each cannula is connected to a separate titanium
alloy valve that uses a pinch-clamp mechanism to allow
needle access under the skin. One valve is for blood draw,
and the other is for blood return. The system must be
disinfected with antimicrobial solution (70% isopropyl al-
cohol) after each use. Tissue hydrostatic pressure keeps the
valves closed when they are not being used.
Since its first description in 1997, the LifeSite catheter
has had moderate clinical success. Most investigators have
found the device superior to conventional hemodialysis
catheters, as would be expected.4-6 However, some authors
noted high infection rates.7 We set out to review our results
at a single tertiary-care university hospital with the LifeSite
Hemodialysis Access System.
METHODS
The individual records of all patients who underwent
placement of a LifeSite Hemodialysis Access System at our
institution were retrospectively reviewed. Data regarding
demographics, duration of hemodialysis-dependent ESRD,
history of prior vascular access, operative details, and post-
operative follow-up were recorded. Significant time points
were dates of occlusion, infection, removal, and death.
Occlusion was defined as malfunction requiring thrombol-
ysis or port exchange. Infection was defined as positive
cultures from the catheter, catheter tract, or catheter tip
that were not regarded as contaminant and were in concor-
dance with the clinical picture of catheter infection. Device
failure was characterized as thrombosis or infection neces-
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sitating catheter removal. All dates of death were either
obtained from or confirmed with the online Social Security
Death Index (http://www.ancestry.com/search/rectype/
vital/ssdi/main.htm).
LifeSite catheter insertion was performed in the oper-
ating room by a vascular surgeon with the aid of fluoros-
copy. One catheter was placed directly into the inferior
vena cava via translumbar puncture by an interventional
radiologist. The technique for catheter placement has been
reported elsewhere.8 Statistics were performed using Stat-
view 5.0.1 software (SAS Institute Inc, Cary, NC). Kaplan–
Meier analysis was used to analyze device patency, patient
survival, freedom from infection, and freedom from device
failure. Events were also reported per 1000 patient-catheter
days for purposes of comparison.
RESULTS
A total of 37 LifeSite catheters were placed in 36
patients at our institution from February 2001 to March
2002. The average age of our cohort was 56 16 years and
44% were males. There were 20 females and 16 males. Our
patients had been receiving hemodialysis for an average of
6.1  4.5 years prior to LifeSite insertion. Etiologies of
ESRD included hypertension (76%), diabetes (46%), sys-
temic lupus erythematosus (8%), and other (16%). Some
patients had more than one contributing factor. Access
target veins included femoral (54%), internal jugular (41%),
and iliac (3%). One patient had direct translumbar insertion
of the LifeSite into the vena cava, as all conventional access
sites were unusable. Almost all patients were referred to our
institution because of difficult access. Twenty-five patients
(68%) had at least three separate failed extremity arterio-
venous fistulas or grafts. This is in addition to countless
graft revisions, thrombectomies, and angioplasties. Femo-
ral Lifesite placement was only attempted if upper extremity
sites were exhausted. In the fraction of patients (68%) who
underwent perioperative ultrasonography or venography to
evaluate central venous patency, 40% showed occlusion of
two central veins or more.
Patient survival was 90%, 86%, and 81% at 3, 6, and 8
months, respectively (Fig 1). A total of 7 patients died
during follow-up. Two patients died perioperatively in the
hospital. One patient died from causes unrelated to cathe-
ter placement (complications arising from upper gastroin-
testinal hemorrhage). The other patient died from septic
shock 3 weeks after a femoral-popliteal bypass with saphe-
nous vein and LifeSite catheter insertion. The cause of
death was thought to be catheter-related sepsis due to
persistent coagulase-negative Staphylococcus bacteremia.
One patient died at 2.5 months from catheter-related sepsis
and another at 8.3 months from sepsis (exact etiology
unknown). The cause of the remaining three deaths is
unknown.
There were 2.4 device infections and 1.4 initial device
occlusions per 1000 days. Freedom from catheter infection
was 80%, 57%, and 46% at 3, 6, and 8 months, respectively
(Fig 2). Of the 14 patients who demonstrated positive
blood or catheter cultures, the overwhelming majority were
infected with gram-positive organisms (93%). Bacterial re-
sistance to methicillin (36%) and vancomycin (7%) was not
uncommon in our population. Two patients with exposed
LifeSite valves were not counted as infections as they were
successfully treated by revision and did not manifest other
signs of clinical infection. Twelve of the 17 patients (71%)
with device infection did not present with symptoms relat-
ing to the valve site; rather, they manifested signs of sys-
temic sepsis such as fever, leukocytosis, and bacteremia.
Often, other sources of infection were ruled out before the
Lifesite was suspected. Femoral catheter infection occurred
in 12 of 18 patients (67%). Femoral LifeSite placement was
not statistically associated with death or infection, however.
Diabetes did not correlate with device infection by the
generalized Wilcoxon rank sum test.
Primary and secondary patency were 86% and 92%, 73%
and 92%, and 62% and 87% at 3, 6, and 8 months, respec-
Fig 1. Survival rates by Kaplan–Meier analysis. Standard error
exceeds 10% at 9.2 months. Two of the first three deaths were from
catheter-related sepsis.
Fig 2. Freedom from infection by Kaplan–Meier analysis. Stan-
dard error exceeds 10% at 7.8 months.
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tively (Fig 3). There were 2.6 device failures per 1000 days.
Freedom from device failure was 93%, 81%, and 49% at 3, 6,
and 8 months, respectively (Fig 4). Eighteen patients (49%)
underwent LifeSite catheter removal due to infection or
thrombosis. Two patients had the LifeSite removed after
successful cadaveric renal transplant, and access was lost
inadvertently during cannula exchange for thrombosis in
another. These three patients were not considered device
failures.
DISCUSSION
Infections have plagued TDC with catheter-related
bacteremia rates ranging from 3.4 to 9.8 events per 1000
patient-catheter days.9-11 These complications have re-
sulted in rising costs associated with vascular access.2 The
LifeSite Hemodialysis Access System was introduced as the
next logical step to combat the high complication rate of
cuffed catheters. Reports of the LifeSite have been gener-
ally favorable in regard to infection and device failure
although no report has focused on patients with difficult
access.
Several series in the literature document an infection
rate of 1.3 to 2.5 per 1000 patient-catheter days.4-6 In an
early study of 23 patients, Beathard and Posen4 found the
LifeSite to have a device failure rate of 2.5 per 1000
patient-catheter days solely due to infection. Neither cath-
eter thrombosis events nor device-related deaths occurred
in their series; however, the infection rate was 52%. A
multicenter study evaluating 45 patients found an infection
rate of 1.9 per 1000 patient-catheter days. Interestingly, all
the device-related infections (12 in 6 patients) occurred in
patients with a history of prior dialysis access. Patients in
this study had a history of prior TDC (71%), and 29%
underwent femoral vein implantation of the LifeSite.5 Fi-
nally, a multicenter prospective randomized trial evaluated
the LifeSite compared with the Tesio-Cath Hemodialysis
Catheter (Med Comp, Harleysville, Pa) and discovered a
low infection rate of 1.3 per 1000 patient-catheter days
when 70% isopropyl alcohol was used as the disinfecting
agent.6
One report cites an alarmingly high infection rate of 4.8
per 1000 patient-catheter days.7 This study describes seven
Fig 4. Freedom from device failure by Kaplan–Meier analysis.
Standard error exceeds 10% at 7.1 months. Device failure was
defined as catheter occlusions or infections requiring device re-
moval.
Fig 3. Primary and secondary patency rates by Kaplan–Meier analysis. Standard error 10% for both curves. Only
catheter occlusions requiring operative intervention were recorded in our database, so actual patency rates may be
lower.
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patients who all have a history of access failure and limited
options for dialysis, similar to our own. Five patients (71%)
developed device-related infection, necessitating removal
in four patients. There were no deaths or thrombosis events
associated with the LifeSite in this review.
Our study describes a patient population that is truly
end-stage. More than two thirds of our patients had at least
three failed arteriovenous fistulas or grafts in addition to
multiple operations for TDC insertion and graft salvage.
Our patient population is chronically ill and debilitated,
typical of a tertiary-care university setting. This is reflected
in the reduced survival rate of only 66% of our patients
surviving at 12 months. Essentially all of our patients
exhausted conventional access sites, which was why our
femoral insertion rate for the LifeSite system is so high
(54%). The paucity of central venous access in these pa-
tients also indicates that they have had ESRD for some time
and are likely preterminal.
Our results show that the infection rate with the
LifeSite Hemodialysis Access System is in concordance with
the rest of the literature at 2.6 per 1000 patient-catheter
days. Although this rate is superior compared with TDC,
the device clearly cannot be used as a substitute for more
permanent dialysis access such as arteriovenous fistulas and
grafts. National Kidney Foundation Dialysis Outcomes
Quality Initiative guidelines12 recommend that dialysis
catheters have infection rates of less than 10% at 3 months
and 50% at 1 year. Our results show that the LifeSite system
does not meet those expectations in patients with limited
access. Perhaps using this device in other patient subgroups
as primary dialysis access may produce more favorable
results.
The relatively high rate of device-related mortality in
this study probably reflects a desire to salvage any form of
dialysis access in this patient population. Most infections
were initially treated with antibiotics, but ultimately,
LifeSite infection usually required removal of the device for
definitive management. At least 2 patients died from cath-
eter-related sepsis and another died from sepsis of unknown
etiology. Our study is the only one published to date that
relates mortality to LifeSite infection. Of concern is that
only 5 of 17 patients who presented with infection mani-
fested symptoms at the valve site. Most patients with cath-
eter infection presented with signs of systemic sepsis: fever,
bacteremia, and leukocytosis. This suggests that the subcu-
taneous nature of the device may mask any early signs of
device-related infection.
Our primary and secondary patency rates are quite
favorable. However, catheter thrombosis was referred to us
only when it required operative intervention. Our rates of
catheter thrombosis are most likely underreported, as we
did not take into account thrombolytic therapy initiated by
the nephrologists for partial occlusions.
In 2001, the Food and Drug Administration reviewed
Vasca’s policies regarding the LifeSite Hemodialysis Access
System.13 According the administration’s report, “The ma-
jority of reported deaths and many reported injuries oc-
curred in patients that were not candidates for permanent
access placement. . . . Many affected patients had a history
of multiple access failures and access infections and would
not be candidates for further permanent access placement.
Moreover, several centers reported patient deaths for indi-
viduals that had been considered ‘last resort’ patients by
their healthcare providers, in that they were not candidates
for permanent access, were very ill, and had limited options
for dialysis access. Several reported deaths and many re-
ported injuries occurred in patients that underwent access
placement procedures (femoral or direct thoracotomy im-
plantation) for which the device is not currently labeled.”
Although Vasca does not describe femoral insertion in
its indications for use, femoral insertion of the LifeSite has
been reported.14 TDC in the femoral location have been
associated with higher infection rates.10 Indeed, the
K/DOQI guidelines recommend against femoral vein can-
nulation if other sites are available.12 In our study, there
was no statistical association between femoral LifeSite
placement and infection or death.
In summary, our results with the LifeSite Hemodialysis
Access System in patients with limited access revealed in-
fection and device failure rates comparable to tunneled
dialysis catheters. The femoral location was not statistically
associated with an increased rate of adverse events. The
LifeSite’s subcutaneous nature may conceal the develop-
ment of infection until sepsis develops. In patients with
limited access and a relatively long history of ESRD, Lifesite
catheter infection may result in death.
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